{"title":"An investigation of the association between Juvenile rheumatic disease and growth: a retrospective matched cohort study.","authors":"Nivethigha Elango, Liza J McCann, David M Hughes","doi":"10.1007/s00296-026-06287-x","DOIUrl":null,"url":null,"abstract":"<p><p>Childhood-onset rheumatic diseases including Juvenile Idiopathic Arthritis (JIA), Juvenile Systemic Lupus Erythematosus (jSLE), and Juvenile Dermatomyositis (JDM) could impact growth, but this is not well described within the UK population, particularly over the long term. This study aims to compare the growth patterns of patients with JIA, jSLE, and JDM to those of their peers. This population-based cohort study used primary care data from the Clinical Practice Research Datalink (CPRD) with follow up through to March 2023. Patients diagnosed with JIA, JDM and jSLE, were matched with up to five healthy controls by age, sex and general practice. Age and sex standardised Z-scores were calculated for height and weight. Linear mixed models were used to investigate differences in growth patterns over time. Height measurements from 3736, 182 and 111 children with JIA, jSLE and JDM and weight measurements from 5088, 251 and 144 children with JIA, jSLE and JDM respectively were extracted. JIA patients showed significant baseline differences in height compared to healthy controls (Estimate= -0.061, 95% CI 0.002, 0.121) but this initial reduction was countered by an increased rate of catch up growth over time. Similar patterns were observed in jSLE and JDM, although differences were less consistent and largely confined to specific subgroups. Overall, weight trajectories were broadly similar to those of matched controls across all three diseases. Stratified analyses suggested that growth patterns varied according to age at disease onset, with the clearest differences observed in JIA. Children with JIA, jSLE and JDM demonstrated altered longitudinal growth patterns, with the clearest evidence observed in JIA. Growth trajectories varied according to age at disease onset, particularly during the pre and peri-pubertal period, suggesting that the timing of disease onset may influence long-term growth. These findings support the importance of longitudinal growth monitoring, particularly among children diagnosed during key developmental periods.</p>","PeriodicalId":21322,"journal":{"name":"Rheumatology International","volume":"46 9","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2026-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13547155/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rheumatology International","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00296-026-06287-x","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Childhood-onset rheumatic diseases including Juvenile Idiopathic Arthritis (JIA), Juvenile Systemic Lupus Erythematosus (jSLE), and Juvenile Dermatomyositis (JDM) could impact growth, but this is not well described within the UK population, particularly over the long term. This study aims to compare the growth patterns of patients with JIA, jSLE, and JDM to those of their peers. This population-based cohort study used primary care data from the Clinical Practice Research Datalink (CPRD) with follow up through to March 2023. Patients diagnosed with JIA, JDM and jSLE, were matched with up to five healthy controls by age, sex and general practice. Age and sex standardised Z-scores were calculated for height and weight. Linear mixed models were used to investigate differences in growth patterns over time. Height measurements from 3736, 182 and 111 children with JIA, jSLE and JDM and weight measurements from 5088, 251 and 144 children with JIA, jSLE and JDM respectively were extracted. JIA patients showed significant baseline differences in height compared to healthy controls (Estimate= -0.061, 95% CI 0.002, 0.121) but this initial reduction was countered by an increased rate of catch up growth over time. Similar patterns were observed in jSLE and JDM, although differences were less consistent and largely confined to specific subgroups. Overall, weight trajectories were broadly similar to those of matched controls across all three diseases. Stratified analyses suggested that growth patterns varied according to age at disease onset, with the clearest differences observed in JIA. Children with JIA, jSLE and JDM demonstrated altered longitudinal growth patterns, with the clearest evidence observed in JIA. Growth trajectories varied according to age at disease onset, particularly during the pre and peri-pubertal period, suggesting that the timing of disease onset may influence long-term growth. These findings support the importance of longitudinal growth monitoring, particularly among children diagnosed during key developmental periods.
儿童期发病的风湿性疾病包括幼年特发性关节炎(JIA)、幼年系统性红斑狼疮(jSLE)和幼年皮肌炎(JDM)可能影响生长,但在英国人群中没有很好地描述,特别是从长期来看。本研究旨在比较JIA、jSLE和JDM患者与同龄人的生长模式。这项基于人群的队列研究使用了临床实践研究数据链(CPRD)的初级保健数据,并随访至2023年3月。诊断为JIA、JDM和jSLE的患者按年龄、性别和一般习惯与多达5名健康对照进行匹配。计算身高和体重的年龄和性别标准化z分数。线性混合模型用于研究随时间变化的生长模式差异。分别提取JIA、jSLE和JDM患儿3736、182和111例的身高数据和JIA、jSLE和JDM患儿5088、251和144例的体重数据。与健康对照相比,JIA患者的基线身高差异显著(估计= -0.061,95% CI 0.002, 0.121),但随着时间的推移,这种最初的降低被追赶增长的速度所抵消。在jSLE和JDM中观察到类似的模式,尽管差异不太一致,并且主要局限于特定的亚组。总体而言,体重轨迹与所有三种疾病的匹配对照大致相似。分层分析表明,生长模式随发病年龄的不同而变化,JIA的差异最明显。JIA、jSLE和JDM患儿表现出纵向生长模式的改变,在JIA中观察到最明显的证据。生长轨迹因发病年龄而异,特别是在青春期前和青春期周围,这表明发病时间可能影响长期生长。这些发现支持纵向生长监测的重要性,特别是在关键发育时期诊断的儿童。
期刊介绍:
RHEUMATOLOGY INTERNATIONAL is an independent journal reflecting world-wide progress in the research, diagnosis and treatment of the various rheumatic diseases. It is designed to serve researchers and clinicians in the field of rheumatology.
RHEUMATOLOGY INTERNATIONAL will cover all modern trends in clinical research as well as in the management of rheumatic diseases. Special emphasis will be given to public health issues related to rheumatic diseases, applying rheumatology research to clinical practice, epidemiology of rheumatic diseases, diagnostic tests for rheumatic diseases, patient reported outcomes (PROs) in rheumatology and evidence on education of rheumatology. Contributions to these topics will appear in the form of original publications, short communications, editorials, and reviews. "Letters to the editor" will be welcome as an enhancement to discussion. Basic science research, including in vitro or animal studies, is discouraged to submit, as we will only review studies on humans with an epidemological or clinical perspective. Case reports without a proper review of the literatura (Case-based Reviews) will not be published. Every effort will be made to ensure speed of publication while maintaining a high standard of contents and production.
Manuscripts submitted for publication must contain a statement to the effect that all human studies have been reviewed by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in an appropriate version of the 1964 Declaration of Helsinki. It should also be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted.